Pathogenesis of mineralocorticoid hypertension.
D000236:Adenoma / Q000150:complications; D000310:Adrenal Gland Neoplasms / Q000150:complications; D000312:Adrenal Hyperplasia, Congenital / Q000150:complications; D000328:Adult; D000450:Aldosterone; D000818:Animals; D001810:Blood Volume; D001826:Body Fluids / Q000378:metabolism; D001835:Body Weight; D002302:Cardiac Output; D003900:Desoxycorticosterone / Q000633:toxicity; D004195:Disease Models, Animal; D005260:Female; D006801:Humans; D006929:Hyperaldosteronism / Q000150:complications; D006973:Hypertension / Q000188:drug therapy / Q000209:etiology*; D007668:Kidney / Q000378:metabolism* / Q000503:physiopathology; D008297:Male; D008901:Mineralocorticoids / Q000502:physiology; D009318:Natriuresis; D011187:Posture; D011188:Potassium / Q000652:urine; D012964:Sodium / Q000378:metabolism*; D013148:Spironolactone / Q000627:therapeutic use; D013564:Sympathetic Nervous System / Q000503:physiopathology; D014655:Vascular Resistance
D008901:Mineralocorticoids; D013148:Spironolactone; D003900:Desoxycorticosterone; D000450:Aldosterone; D012964:Sodium; D011188:Potassium